Bristol Myers Squibb and Bain Capital have formed a new independent biopharmaceutical company focused on developing new ...

The $139 billion TAMP has hired industry veteran Phil Rogerson, unveils $10 million commitment for strategic expansion in ...

A new startup offering an AI-enabled threat-hunting platform is emerging from stealth today with backing from Bain Capital ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...

The biopharma spinoff will advance the development of its five investigational therapies designed to treat autoimmune disease.

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

The increasing appeal of the German market was evidenced this week with the news that PE firm Bridgepoint is close to signing ...

Bristol Myers Squibb is taking a strategic leap, offloading five immunology assets, including three in clinical stages, to a ...